Enterprise Value
342.5M
Cash
264.9M
Avg Qtr Burn
-29.1M
Short % of Float
8.72%
Insider Ownership
0.39%
Institutional Own.
95.79%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ANX005 (IV) Details Guillian-Barre syndrome, Autoimmune disease | BLA Submission | |
ANX007 (IVT) Details Geographic atrophy | Phase 3 Update | |
ANX005 (IV) Details Brain disease, Huntington's disease | Phase 3 Initiation | |
ANX005 (IV) Details Amyotrophic lateral sclerosis, Neurodegenerative disease | Phase 2a Update | |
ANX009 Details Lupus nephritis | Phase 1b Update | |
ANX105 Details Autoimmune disease, Neurodegenerative disease | Phase 1 Data readout | |
ANX1502 Details Autoimmune disease, Cold agglutinin disease | Phase 1a Data readout | |
ANX005 (IV) Details Warm autoimmune hemolytic anemia, Autoimmune disease | Failed Discontinued |